相关临床试验
5
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
4
80.0%
已完成
1
20.0%
暂无批准数据
- The global AI in drug repurposing market is projected to surge from $1.28 billion in 2025 to $10.56 billion by 2035, reflecting a 23.4% CAGR driven by demand for faster, cost-efficient drug discovery. - Machine learning and deep learning technologies dominate the market, while oncology leads application segments due to high global cancer incidence and urgent need for novel therapies. - North America holds the largest market share, supported by advanced healthcare infrastructure and strong adoption of AI technologies among pharmaceutical and biotech firms. - Key players including BenevolentAI, Insilico Medicine, and BioXcel Therapeutics are advancing AI platforms that compress candidate identification timelines and improve clinical success rates.
- Paris-based Generare raised €20 million in Series A funding to expand its platform that decodes microbial genomes to discover previously inaccessible small molecules for drug discovery. - The company discovered more than 200 novel molecules in 2025 alone, outpacing all other players in the field combined who found only a few dozen new compounds. - Generare aims to scale its molecular library tenfold by 2027 to over 2,000 molecules, targeting the estimated 97% of genomic data buried in unexplored microbial genomes. - The funding will support expansion of the company's proprietary dataset and platform capabilities, positioning it to supply differentiated chemical starting points for next-generation AI drug discovery algorithms.
- Formation Bio appointed four senior executives including Louis Brenner, MD as Chief Medical Officer and Daniel Neil, PhD as Chief Technology Officer to strengthen its AI-native pharmaceutical model. - Former Pfizer CFO Frank D'Amelio and ex-Incyte CSO Dashyant Dhanak, PhD joined as Strategic Advisors to guide the company's drug licensing and acquisition decisions. - The leadership expansion supports Formation Bio's plan to grow its pipeline from current assets to 10-15 drug candidates over the next 3-5 years. - The company recently secured a €545M out-licensing deal and added a new autoimmune disease asset to its development portfolio.
• Google has announced TxGemma, a collection of open AI models designed to streamline drug discovery by understanding both text and therapeutic entity structures, set for release through its Health AI Developer Foundations program. • Built on the Gemma model family, TxGemma comes in three sizes (2B, 9B, and 27B parameters) with specialized versions for classification, regression, and generation tasks, outperforming specialized models in 64 of 66 key benchmarks. • The initiative aims to address the high failure rate in drug development, where 90% of candidates don't progress past phase 1 trials, by enhancing prediction capabilities across the research pipeline from target identification to clinical trial outcomes.
• Verge Genomics has initiated Phase 1 clinical trials for VRG50635, a novel PIKfyve inhibitor discovered using their AI platform ConVERGE, marking a significant milestone in AI-driven drug development. • The drug candidate, developed in just four years, targets a novel mechanism involving lysosomal function in ALS, demonstrating promising neuron preservation effects in preclinical studies. • This achievement positions Verge Genomics among select companies successfully transitioning AI-discovered drugs to clinical trials, supported by major pharmaceutical investors including Eli Lilly and Merck & Co.
• AI is revolutionizing drug discovery by accelerating target identification, drug molecule design, and clinical development, potentially reducing costs and increasing the probability of success in Phase 2 trials. • Generative AI analyzes vast datasets to identify promising drug candidates and predict molecular interactions, while AI-focused biotechs are rapidly advancing drug candidates into clinical trials. • AI is enhancing clinical trial efficiency through automated data analysis, predictive modeling for site selection, improved patient engagement, and faster recruitment, leading to quicker trial completion and reduced participant numbers. • The integration of AI in drug discovery and development promises faster, cheaper, and better-value outcomes by minimizing experimental overhead, improving trial efficiency, and balancing drug properties.
- Artificial Intelligence has emerged as a transformative force in pharmaceuticals, revolutionizing processes from drug discovery to patient care, with demonstrated success in reducing development timelines and costs. - AI applications span the entire pharmaceutical value chain, including drug repurposing, clinical trial optimization, and supply chain management, with companies like Insilico and Benevolent AI showcasing breakthrough achievements. - Implementation of AI in pharma has shown remarkable efficiency gains, including 30% cost reduction in supply chain optimization and 82-92% reduction in literature monitoring time for medical affairs.
- Machine learning and AI technologies are transforming pharmaceutical R&D, with industry experts projecting potential annual value generation of $100 billion through improved decision-making and research efficiency. - Leading companies including IBM Watson Health, Google's DeepMind, Berg, and BenevolentAI are pioneering AI applications in areas ranging from cancer genomics to eye disease diagnosis and drug candidate screening. - Major pharmaceutical companies like Merck, GSK, and Pfizer are actively embracing AI through strategic partnerships, marking a significant shift in traditional drug discovery approaches.
- BenevolentAI and MRC Technology have formed a two-year collaboration to identify and validate novel small molecule and antibody drug candidates using artificial intelligence technology. - The partnership combines BenevolentAI's deep learning platform with MRCT's screening and drug development capabilities to streamline the discovery of new medicines. - BenevolentAI's advanced AI system, powered by NVIDIA DGX-1 supercomputer, positions the company as a leading competitor in the growing field of AI-driven pharmaceutical research.
